Abstract
Regenerative medicine offers hope to close the gap between organ failure and transplant availability, but progress remains incremental. This editorial reviews early clinical triumphs, such as cultured skin grafts and tissue-engineered bladders and vaginas, and contrasts them with persistent barriers to whole-organ replacement. We examine stem cell interventions that show functional gains in small trials (for example, cardiopoietic cells and stem-cell-derived islets) yet lack long-term evidence, consistent manufacturing, and proven survival benefit. Tissue engineering advances, including decellularization, perfusion bioreactors, and three-dimensional bioprinting, demonstrate feasibility for simple constructs but fall short for complex organs that require integrated vasculature and multiple specialized cell types. We highlight safety concerns such as thromboembolism and fibrosis, variable product quality, and the risk posed by unregulated clinics. Ethical, regulatory, and economic obstacles, including unclear approval pathways, absent long-term registries, high costs, and potential inequities, threaten translation. To advance patient-centered care, we call for rigorous and transparent clinical trials, shared manufacturing standards, mandatory long-term follow-up, and multidisciplinary collaboration focused on near-term clinically impactful strategies alongside long-term organ engineering research. Humility, vigilance, and alignment of innovation with clinical need are essential if lab-grown organs are to become safe and equitable therapies.